Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market
Mandate

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market

April 29, 2022 Capital Markets and Public M&A

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 29 April 2022. In connection with the listing, a shares subscription offer was performed at a subscription price of SEK 16.

Promimic AB is a biomaterials company which produces and markets HAnano Surface, a unique coating for medical implants which strengthens their anchoring in bone tissue. Promimic focuses on the dental and orthopaedic implant market.

Vinge’s team consisted primarily of Anders Strid, Johanna Hamrefält (project manager), Adrian Filipovic, Rebecka Hansson, Anna Högsten and Fredrik Löwenclou.

 

Related

Vinge has advised Morrow Bank in connection with its issuances of primary capital instruments (AT1) and tier 2 capital bonds (T2)

 The issuances comprised perpetual AT1 bonds of NOK 300 million with a floating coupon of 3-month NIBOR + 425 basis points and a first call date in 2031, as well as subordinated Tier 2 bonds of SEK 200 million with a floating coupon of 3-month STIBOR + 325 basis points and a first call date in 2031. The bonds are intended to be admitted to trading on Nasdaq Stockholm.
July 03, 2026

Vinge advises Wihlborgs Fastigheter in connection with the financing of property acquisition valued at SEK 13.3 billion

 Vinge advises Wihlborgs Fastigheter AB (publ) in connection with the financing of the acquisition of all of Castellum’s property holdings in Malmö, Lund and Helsingborg. The financing has been secured through Danske Bank, SEB and Swedbank.
June 29, 2026

Vinge advises Ambea on the public offer for Humana

 Ambea AB (publ) has made a public offer for all shares in Humana AB. The offer values all shares in Humana at approximately SEK 2,96 billion. The consideration consists of a mix of shares, cash and a CVR (contingent value right).
June 29, 2026